Phosphodiesterases (PDEs) are a family of related phosphohydrolyases that selectively catalyze the hydrolysis of 3' cyclic phosphate bonds in adenosine and/or guanine 3',5' cyclic monophosphate (cAMP and/or cGMP). They regulate the cellular levels, localization and duration of action of these second messengers by controlling the rate of their degradation.
There are 11 subtypes of PDEs, named PDE1-11; PDE4, 7 and 8 selectively degrade cAMP, PDE5, 6 and 9 selectively degrade cGMP and PDE1, 2, 3, 10 and 11 degrade both cyclic nucleotides. PDEs are expressed ubiquitously, with each subtype having a specific tissue distribution. These enzymes are involved in many signal transduction pathways and their functions include vascular smooth muscle proliferation and contraction, cardiac contractility, platelet aggregation, hormone secretion, immune cell activation, and they are involved in learning and memory.
To view external sources of pharmacological information for Phosphodiesterases, please click here: BJP GuideView all products for Phosphodiesterases »
|Gene||Species||Gene Symbol||Gene Accession No.||Protein Accession No.|
|View all Phosphodiesterase Gene Data »|
Literature for Phosphodiesterases
A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:
- Thrombosis and Hemostasis
- Myocardial Infarction
- Ischemia/Reperfusion Injury
- Heart Failure
Written by Peter Barnes, this poster highlights key pathways in the development of asthma. Special focus is given to new therapies used to treat asthma, including those currently in clinical development; treatment pathways include lipid mediator inhibitors, cytokine modulators and mast cell-directed therapies. Compounds available from Tocris are listed.Request copy | View all posters